Core Insights - HUTCHMED will host a Research & Development update on October 31, 2025, in Shanghai and via webcast [1][2] Group 1: Event Details - The event will feature Dr. Michael Shi, who will discuss the company's R&D strategy, including the Antibody Targeted Therapy Conjugates platform and updates on late-stage pipeline development [2] - The in-person event will take place from 3:00 p.m. to 5:00 p.m. HKT and will be conducted in Chinese, with a live English webcast at 8:00 p.m. HKT [3] - Both webcasts will be available live on the company website, with a replay accessible shortly after the event [4] Group 2: Company Overview - HUTCHMED is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [5] - The company has successfully marketed its first three medicines in China, with the first also approved globally, including in the US, Europe, and Japan [5]

Core Viewpoint - HUTCHMED announces the temporary leave of its CEO Dr. Weiguo Su due to health reasons, with CFO Johnny Cheng appointed as Acting CEO to ensure continuity in operations and strategy execution [1][2]. Company Leadership Changes - Dr. Weiguo Su, the Executive Director and CEO, is taking a leave of absence for health reasons, emphasizing the need to focus on his recovery [1][2]. - Johnny Cheng, currently the Executive Director and CFO, has been appointed as Acting CEO, effective immediately, while continuing his role as CFO [1][2]. Board Support and Confidence - The Board of Directors expresses full support for Dr. Su and confidence in Mr. Cheng's capabilities to manage the company during this interim period [2]. - The Board reassures stakeholders that all research, development, and commercial initiatives will remain on track despite the leadership change [2]. Company Overview - HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [3]. - The company has successfully marketed its first three medicines in China, with the first also approved in global markets including the US, Europe, and Japan [3].

Core Insights - HUTCHMED is set to present new data on its compounds at the ASCO Annual Meeting from May 30 to June 3, 2025, in Chicago, USA [1] Group 1: Savolitinib - The SACHI Phase III study results of savolitinib in combination with osimertinib for EGFR mutation-positive NSCLC will be presented, showing that it met the primary endpoint of progression-free survival (PFS) [2] - Additional data from the SAVANNAH Phase II study indicates that the combination of savolitinib and osimertinib showed better efficacy outcomes compared to savolitinib plus placebo, with promising CNS activity [3] Group 2: Ranosidenib - Results from the Phase I study of ranosidenib (HMPL-306) indicate it was well tolerated, with target inhibition and durable responses, particularly in lower-grade glioma patients, showing an objective response rate (ORR) of 7.1% and a disease control rate (DCR) of 100% [4] Group 3: Fruquintinib - The FRUSICA-1 Phase II study results for fruquintinib plus sintilimab in advanced endometrial cancer patients showed an ORR of 37.0% and a DCR of 88.9%, with durable responses regardless of prior chemotherapy [5] - A Phase IV study involving 2,798 colorectal cancer patients demonstrated a manageable safety profile for fruquintinib, with Grade 3 or above treatment-emergent adverse events occurring in 23.94% for monotherapy and 26.06% for combination therapy [6]

Company Overview - HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [6] - The company retains all rights to fanregratinib worldwide [4] Clinical Trial Details - HUTCHMED has completed enrollment for a Phase II trial of fanregratinib (HMPL-453) targeting intrahepatic cholangiocarcinoma (IHCC) patients with FGFR2 fusion/rearrangement [1][2] - The trial is a single-arm, multi-center, open-label study with a primary endpoint of objective response rate (ORR) and secondary endpoints including progression-free survival (PFS), disease control rate (DCR), duration of response (DoR), and overall survival (OS) [2] - A total of 87 patients were enrolled in the registration phase of the study, with topline results expected to be announced around the end of 2025 [2][3] Product Information - Fanregratinib is a novel, highly selective, and potent inhibitor targeting FGFR 1, 2, and 3, which are implicated in tumor growth and resistance to therapies [4] - Aberrant FGFR signaling is recognized as a driving force in tumor growth, and abnormal FGFR gene alterations are believed to drive tumor cell proliferation in various solid tumors [4] Market Context - In China, an estimated 61,900 new cases of IHCC were diagnosed in 2015, with an annual incidence increase of 9.2% from 2006 to 2015 [5] - FGFR2 fusion has a reported prevalence of 10-15% among IHCC patients [5]